Physician profile
Peter E Blackstone
NPI 1053391854
$9,962.99
in general payments reported to CMS, 2019-2025
57 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $230 · 2021: $841 · 2022: $1,976 · 2023: $1,679 · 2024: $1,655 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,042 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,042.02 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,322.64 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $1,233.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $982.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $875.85 | 2019-2025 | |
| Lilly USA, LLC | $548.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $395.16 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $342.00 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $329.86 | 2021-2025 | |
| Amgen INC. | $322.52 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $314.55 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Novartis Pharmaceuticals Corporation | $303.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $302.19 | 2019-2025 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $299.65 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.93 | 2019-2025 | Jardiance |
| Abbott Laboratories | $230.74 | 2021-2025 | Freestyle Libre 3 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Blackstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.